The purpose of this study is to determine whether treatment with OP-1250 as a monotherapy will result in improvement of progression-free survival (PFS) and overall survival (OS) compared to SOC ET and assess the safety of treatment with OP-1250 in participants with ER+, HER2– advanced or MBC with and without estrogen receptor 1 gene (ESR1) activating mutation(-s) whose disease has relapsed or progressed on 1 or 2 prior lines of SOC ET, including a cyclin-dependent kinase (CDK) 4/6 inhibitor.
Service
No matter where you call home, our home care team will meet you where you are and deliver care that puts comfort, quality of life and independence first. From helping with everyday chores to ongoing treatment for chronic illness, our visiting nurses and care team will be there for you every step of the way. ...